Features - Medical Marketing and Media

RSS | Login | Register

Latest Features

Headliner: Hayes' open-door policy opens doors

James Chase May 01, 2012

Tim Hayes, President, Bayer HealthCare Consumer Care North America

MM&M Awards: Dream Team 2012

James Chase May 01, 2012

This year's judges for the MM&M Awards once again represent the cream of the industry's leaders and thinkers. But this year, there are twice as many of them. Find out who made it onto the panel

Product Communications: When Love Is Blind

Fred Kinch May 01, 2012

Getting too enamored of products can lead to losing sight of customer needs. Fred Kinch on how to avoid being blinded by product devotion

Med Ed Report: Show Me the Money

Fred Kinch May 01, 2012

Following industry's CME cutback, dinner meetings and other kinds of peer-to-peer interaction are grabbing more of its meeting spend. How much more, and is this good for medical education? David Rear reports

Pharma Report 2012: Get Back in Shape

Marc Iskowitz May 01, 2012

When big pharma looks in the mirror, what does it see? A body beset by old, expiring brands and not enough energetic, youthful ones to replace them. Marc Iskowitz has industry's regimen for regaining form

Headliner: Easing NEJM into its third century

Tanya Lewis April 01, 2012

Tom Easley, publisher, managing director of The New England Journal of Medicine

Journal Ad Review 2011: On a Tear

Marc Iskowitz April 01, 2012

Medical/surgical journal advertising grew in 2011, the second consecutive year it's been in the black. Marc Iskowitz on which categories and brands attracted the most advertising dollars

Orphan Drugs: Small is the New Big

Deborah Weinstein April 01, 2012

Orphan drug approvals are up, thanks to marketing exclusivity and development incentives. Deborah Weinstein charts the industry's drive to think small, highlighting tactics for drawing attention

MM&M Therapeutic Focus: Metabolic

Noah Pines April 01, 2012

With the FDA weighing a new Rx diet therapy, we review the anti-obesity sector. Noah Pines on the hype and hurdles for Vivus's Qnexa and its would-be competitors, and the diabetes controversy

DTC: Beyond the Blockbuster

Matthew Arnold April 01, 2012

The mass-market, TV-and-print DTC formula is going the way of the vanishing primary care blockbusters it was designed to boost as new media and niche products fill the breach, Matthew Arnold reports

Headliner: Making tomorrow's portal personal

Tanya Lewis March 01, 2012

Jeff Arnold, co-founder, chairman and CEO, Sharecare

MAHF Inductees 2012: Heroes' Welcome

James Chase March 01, 2012

It was a night to remember as the stars of medical advertising came out to welcome three more legends into the Hall of Fame

Co-pay Cards: House of Cards

Larry Blandford March 01, 2012

Co-pay cards have proliferated, undermining payer benefit plans. Now, insurers are striking back against the cards.

Specialty Pharma: Niches to Riches

Noah Pines March 01, 2012

Specialty biopharma firms are using razor-sharp therapeutic focus to target "niche buster" categories.

State of Market Research: Analyze This

Marc Iskowitz March 01, 2012

Market research must transform itself or run the risk of becoming obsolete. Marc Iskowitz teams with the PMRG and TGaS Advisors to review the cold hard facts

MM&M Awards 2012: How to Win an Award

James Chase March 01, 2012

James Chase asked 16 of last year's judges about how entrants can improve their chances of winning an MM&M Award

MM&M Awards: The Hunt for Red October

James Chase February 01, 2012

The MM&M Awards 2012 program is open for business.

Managed Care: Preferential Treatment

Elizabeth Jeffords February 01, 2012

Pharma firms are partnering with managed care companies to find drug evidence and improve outcomes. Can this strategy provide the proof payers demand before giving products preferential treatment?

Medical Advertising Hall of Fame: Lasting Legends

February 01, 2012

The Medical Advertising Hall of Fame's three new members have had exceptional lives and careers. We look back at their achievements

MM&M Therapeutic Focus: Cardiovascular

Noah Pines February 01, 2012

New cardiovascular treatments are gaining FDA approval as massive brands lose patent protection. Noah Pines on the potential of these new entrants to replace that lost revenue

Click here for MM&M’s guide to Healthcare Agencies

Subscribe to the RSS for this page [view all our RSS feeds here]

Video Exclusive

Web Exclusives

Five industry experts advise specialty pharma company on digital strategy

April 20, 2012

Specialty pharma company POZEN assembled a crack team of experts to help shape its digital strategy. Not only did POZEN share with us the text from their contributions, but you can watch exclusive video clips of their valuable perspectives right here.